At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 64 enrolled
Drug / intervention
CVN766drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating CVN766 for Safety Issues and Tolerance. Completed, enrolled 64 participants across 1 site.
Detailed Summary
Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSafety Issues, Tolerance
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartJan 2022
Primary CompletionOct 2022
Study CompletionNov 2022
TodayJul 2026
First PostedNov 3, 2021
Enrollment StartJan 17, 2022
Primary CompletionOct 30, 2022
Study CompletionNov 21, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.7 years ago
Interventions
CVN766drug
highly selective orexin-1 receptor (Ox1R) antagonist